Enliven Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,039	570	108	59	384
Market Cap Growth	406.37%	430.51%	81.86%	-84.60%	-
Enterprise Value	715	317	32	-31	296
PE Ratio	-	-7.97	-2.85	-1.15	-7.80
PB Ratio	3.26	2.32	-1.40	0.69	4.55
P/FCF Ratio	-11.38	-9.29	-3.29	-1.26	-10.26
P/OCF Ratio	-11.40	-9.31	-3.35	-1.26	-10.26
EV/EBITDA Ratio	-5.15	-4.47	-0.85	0.59	-7.16
EV/EBIT Ratio	-5.11	-4.43	-0.85	0.59	-7.15
EV/FCF Ratio	-6.36	-5.16	-0.98	0.65	-7.90
Debt / Equity Ratio	-	-	-	0.01	-
Debt / EBITDA Ratio	-	-	-	-0.01	-
Debt / FCF Ratio	-	-	-	-0.01	-
Quick Ratio	12.81	9.78	7.78	12.52	14.12
Current Ratio	13.47	10.28	8.00	12.86	14.47
Return on Equity (ROE)	-28.80%	-26.60%	430.40%	-63.10%	-50.40%
Return on Assets (ROA)	-27.00%	-25.20%	-51.90%	-57.90%	-47.70%
Return on Capital (ROIC)	-29.30%	-33.97%	50.49%	-59.35%	-49.38%
Earnings Yield	-7.69%	-12.55%	-35.03%	-86.91%	-12.82%
FCF Yield	-6.17%	-10.77%	-30.40%	-79.13%	-9.75%
Buyback Yield / Dilution	-127.09%	-1037.74%	42.31%	-55.56%	-1882.29%
Total Shareholder Return	-127.09%	-1037.74%	42.31%	-55.56%	-1882.29%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).